Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma

Figure 2 An example of follow-up medical record of camrelizumab plus apatinib and hepatic artery infusion chemotherapy treatment in hepatocellular carcinoma patients with tumor thrombus of right inferior portal vein. A 48-year-old male patient with hepatocellular carcinoma (arrow) were examined [the maximum diameter, 13.1 cm; location in S4/8; alpha-fetoprotein (AFP), > 121000 ng/mL] by contrast enhanced magnetic resonance imaging scanning on July 2021. A-C: Preoperative scan [T1WI portal phase]; D-F: After two-cycle camrelizumab plus apatinib and hepatic artery infusion chemotherapy (TRIPLET), the tumor (arrow) has shrunk (the maximum diameter, 7.7 cm; AFP, 10616.0 ng/mL) (T1WI portal phase); G-I: After four-cycle TRIPLET, the tumor (arrow) has shrunk significantly (the maximum diameter, 7.0 cm; AFP, 6183.00 ng/mL) (T1WI portal phase).